Cargando…
National landscape assessment of academic medical center support for expanded access to investigational products
Expanded access (EA) provides a pathway for the clinical use of investigational products (drugs, biologics, and medical devices) for patients who are without satisfactory therapeutic options and for whom a clinical trial is not available. Academic medical centers (AMCs) are likely to encounter EA re...
Autores principales: | Gravelin, Misty, Adamo, Joan E., Ellison, Sharon, Segear, Erika, Parrish, Amanda B., Deeter, Christine, Hamill, Jennifer, Rigan, Laurie, Mashour, George A., Weatherwax, Kevin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879891/ https://www.ncbi.nlm.nih.gov/pubmed/36755539 http://dx.doi.org/10.1017/cts.2022.494 |
Ejemplares similares
-
400 Exploring the Diversity of Expanded Access Patients at Michigan Medicine
por: Gravelin, Misty, et al.
Publicado: (2023) -
2276 Development of the expanded access oversight committee at Michigan Medicine
por: Weatherwax, Kevin, et al.
Publicado: (2018) -
Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights
por: Holbein, M. E. Blair, et al.
Publicado: (2018) -
Adapting an Expanded Access program to enable investigational treatments for COVID-19
por: Samuels, Elias, et al.
Publicado: (2022) -
Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic
por: Gravelin, Misty, et al.
Publicado: (2021)